米非司酮单用与联合止痛化症胶囊治疗子宫腺肌症疗效比较  

Effects of using mifepristone alone or combined with resolving stasis resolving and killing pain capsules for adenomyosis

作　　者：曾雪英 李伟宏[2] 

机构地区：[1]海南现代妇婴医院妇产科 [2]海南医学院附属医院妇产科,海南海口570206

出　　处：《海南医学院学报》2012年第12期1790-1791,1796,共3页Journal of Hainan Medical University

基　　金：中国高校医学期刊临床专项资金项目(112210452)~~

摘　　要：目的:探讨止痛化症胶囊联合米非司酮与单纯应用米非司酮治疗子宫腺肌症的临床疗效。方法:将诊断为子宫腺肌症的患者随机分成观察组和对照组,每组各40例,对照组口服米非司酮12.5mg/d,连续3个月,观察组在服用米非司酮基础上加服止痛化症胶囊4粒/次,3次/d,连服3个月,停药3个月,观察痛经改善及血清CA125变化情况。结果:两组患者服药3个月全部闭经,停药后血清CA125下降水平差异无统计学意义。停药3个月后全部复经,血清CA125水平对照组高于观察组(t=3.64,P﹤0.01);治疗前两组痛经评分差异无统计学意义,停药后3个月痛经评分,观察组低于对照组(P﹤0.01)。结论:米非司酮联合止痛化症胶囊治疗子宫腺肌症疗效确切,停药3个月痛经评分低于单纯使用米非司酮者,有临床实用价值。Objective： To evaluate the clinical efficacy of using Mifepristone alone or combined with resolving stasis resolving and killing pain capsules for adenomyosis.Methods： Eighty adenomyosis patients were randomly divided into observation group and control group by half.The control group was given oral mifepristone at the dosage of 12.5 mg/d for 3 consecutive months.While the observation group was also given resolving stasis resolving and killing pain capsules,4 capsules per time,3 times / d based on mifepristone therapy.Three months after withdrawal of drugs,dysmenorrhea and change of serum CA125 were observed and compared.Results：After medication,ministration circle stopped in all patients,and serum CA125 level all decreased,but the difference was not significant.Three months after withdrawal of drugs,all patients got their circle again,but the serum CA 125 of the control group was significant higher than that of the observation group（t=3.64,P0.01）;dysmenorrhea score of the observation group was significant lower that that of the control group 3 months after withdrawal of drugs,though no significant difference was found before the treatment.（P0.01）.Conclusion： Mifepristone combining with resolving stasis resolving and killing pain capsules is effective on adenomyosis,and efficacy is superior to that using mifepristone alone.

关 键 词：子宫腺肌症 止痛化症胶囊 米非司酮 

分 类 号：R711.32[医药卫生—妇产科学]